← Back to Clinical Trials
Recruiting Phase 2 NCT05914389

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

Trial Parameters

Condition Colon Neoplasm
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2023-08
Completion 2025-08
Interventions
OxaliplatinCapecitabineAnti-PD-L1 Monoclonal Antibody

Brief Summary

This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years old and ≤75 years old. * Pathologically diagnosed MSS or pMMR-type colon adenocarcinoma. * The lower edge of the tumor is more than 12cm from the anus as measured by colonoscopy and the lower edge of the tumor cannot be directly palpated during rectal examination. * Enhanced CT stage T3/4 or T1-4N+ without multiple primary tumors or distant metastasis. * Life expectancy is expected to be more than 1 year. * First diagnosis, no previous anti-tumor treatment received, and no chemotherapy contraindications. * Informed consent, able to understand the study protocol and willing to participate in the study, and will provide written informed consent. Exclusion Criteria: * Refused to participate in this study. * Multifocal colorectal cancer. * History of malignant tumors, except for basal cell carcinoma, papillary thyroid carcinoma, and various in situ cancers. * Cannot tolerate chemotherapy, such as but not limited to bone marrow suppression. * Acute exacer

Related Trials